Amgen executive VP/chief tech officer retiring after 21 years
Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years.
Reese, an M.D., joined the global life sciences powerhouse in 2005 as a clinical development leader in oncology and later served as executive vice president of research and development from 2018 to 2023.
His retirement is effective June 30.
During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities, Amgen said in a press release.
As inaugural chief technology officer, Reese encouraged the early adoption of technology and artificial intelligence across all facets of the business, in particular R&D.
“Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift,” Robert Bradway, the biotech company’s chair/CEO, said in a press release.
“The capabilities he built position us to advance what we call convergent innovation and strengthen our ability to serve patients in the years ahead,” Bradway said.
Convergent innovation brings together biology, data science, and advanced technologies such as artificial intelligence, to accelerate the discovery and development of new medicines and transform how patients, providers and other partners engage with the health care system.
Amgen is evolving its organization to better connect these interactions with how the company operates, according to the press release.
To support this, Amgen is making the following changes effective June 1:
- Jame Bradner, M.D., will serve as executive vice president, research and development, AI and data.
- Sean Bruich will serve as senior vice president, chief technology officer.
- Murdo Gordon will serve as executive vice president, Amgen Global Markets and Policy.
Paul Burton, M.D., meanwhile, will continue to serve as senior vice president, chief medical officer.
“Together, these changes deepen the integration of science and technology and align the organization with the evolving adoption of new technologies across the health care ecosystem, supporting Amgen’s ability to serve more patients around the world,” the company said in the release.
